New drug shows promise for rare bone cancer patients

NCT ID NCT04278781

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 24 times

Summary

This study tests whether the drug AG-120 can safely control tumor growth in people with advanced or recurrent chondrosarcoma, a rare bone cancer, that has a specific IDH1 gene mutation. Six adults with grade 2 or 3 disease are enrolled. The main goal is to see how long the cancer stays stable or shrinks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University (Specimen Analysis Only)

    New York, New York, 10032, United States

  • Johns Hopkins Hospital (Data Collection Only)

    Baltimore, Maryland, 21287, United States

  • MD Anderson Cancer Center (Data Collection Only)

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • The Ohio State University (Data Collection Only)

    Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.